Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/PTEN_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/PTEN_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/PTEN_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/PTEN_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/PTEN_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/PTEN_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/PTEN_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/PTEN_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/PTEN_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:015011618 | Oral cavity | EOLP | regulation of cell-substrate junction organization | 25/2218 | 71/18723 | 2.54e-07 | 7.85e-06 | 25 |
GO:001631114 | Oral cavity | EOLP | dephosphorylation | 85/2218 | 417/18723 | 3.19e-07 | 9.47e-06 | 85 |
GO:001605523 | Oral cavity | EOLP | Wnt signaling pathway | 89/2218 | 444/18723 | 3.66e-07 | 1.06e-05 | 89 |
GO:019873823 | Oral cavity | EOLP | cell-cell signaling by wnt | 89/2218 | 446/18723 | 4.49e-07 | 1.25e-05 | 89 |
GO:007190023 | Oral cavity | EOLP | regulation of protein serine/threonine kinase activity | 75/2218 | 359/18723 | 5.81e-07 | 1.53e-05 | 75 |
GO:003300212 | Oral cavity | EOLP | muscle cell proliferation | 56/2218 | 248/18723 | 1.25e-06 | 3.00e-05 | 56 |
GO:004573226 | Oral cavity | EOLP | positive regulation of protein catabolic process | 53/2218 | 231/18723 | 1.43e-06 | 3.42e-05 | 53 |
GO:001635815 | Oral cavity | EOLP | dendrite development | 55/2218 | 243/18723 | 1.43e-06 | 3.42e-05 | 55 |
GO:000166624 | Oral cavity | EOLP | response to hypoxia | 65/2218 | 307/18723 | 2.00e-06 | 4.55e-05 | 65 |
GO:001097515 | Oral cavity | EOLP | regulation of neuron projection development | 86/2218 | 445/18723 | 2.75e-06 | 6.05e-05 | 86 |
GO:001063219 | Oral cavity | EOLP | regulation of epithelial cell migration | 62/2218 | 292/18723 | 3.09e-06 | 6.74e-05 | 62 |
GO:004865915 | Oral cavity | EOLP | smooth muscle cell proliferation | 44/2218 | 184/18723 | 3.47e-06 | 7.48e-05 | 44 |
GO:007048224 | Oral cavity | EOLP | response to oxygen levels | 70/2218 | 347/18723 | 5.00e-06 | 1.02e-04 | 70 |
GO:003629324 | Oral cavity | EOLP | response to decreased oxygen levels | 66/2218 | 322/18723 | 5.31e-06 | 1.07e-04 | 66 |
GO:003235522 | Oral cavity | EOLP | response to estradiol | 36/2218 | 141/18723 | 5.44e-06 | 1.08e-04 | 36 |
GO:190204122 | Oral cavity | EOLP | regulation of extrinsic apoptotic signaling pathway via death domain receptors | 18/2218 | 49/18723 | 6.01e-06 | 1.19e-04 | 18 |
GO:004354210 | Oral cavity | EOLP | endothelial cell migration | 59/2218 | 279/18723 | 6.05e-06 | 1.19e-04 | 59 |
GO:004477222 | Oral cavity | EOLP | mitotic cell cycle phase transition | 81/2218 | 424/18723 | 8.32e-06 | 1.59e-04 | 81 |
GO:190336426 | Oral cavity | EOLP | positive regulation of cellular protein catabolic process | 38/2218 | 155/18723 | 8.47e-06 | 1.61e-04 | 38 |
GO:006145824 | Oral cavity | EOLP | reproductive system development | 81/2218 | 427/18723 | 1.09e-05 | 1.93e-04 | 81 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389N>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A2-A4RX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | | c.404T>A | p.Ile135Lys | p.I135K | P60484 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389G>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-A7-A4SC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTEN | SNV | Missense_Mutation | | c.593N>A | p.Met198Lys | p.M198K | P60484 | protein_coding | deleterious(0) | benign(0.285) | TCGA-AC-A2FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
PTEN | SNV | Missense_Mutation | | c.384N>C | p.Lys128Asn | p.K128N | P60484 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | | c.28N>C | p.Ser10Arg | p.S10R | P60484 | protein_coding | deleterious(0) | benign(0.188) | TCGA-AR-A1AJ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PTEN | SNV | Missense_Mutation | rs786201995 | c.70G>A | p.Asp24Asn | p.D24N | P60484 | protein_coding | deleterious(0) | benign(0.012) | TCGA-AR-A1AM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
PTEN | SNV | Missense_Mutation | | c.367C>G | p.His123Asp | p.H123D | P60484 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PTEN | SNV | Missense_Mutation | | c.370N>A | p.Cys124Ser | p.C124S | P60484 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AR-A2LL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
PTEN | SNV | Missense_Mutation | rs121909229 | c.389N>A | p.Arg130Gln | p.R130Q | P60484 | protein_coding | deleterious(0.02) | probably_damaging(0.998) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PI3KBETA INHIBITOR AZD8186 | | 25544636 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | TEMSIROLIMUS | TEMSIROLIMUS | 11504908,23674493 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Temsirolimus | TEMSIROLIMUS | 27016228 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PF-04691502 | PF-04691502 | 21750219 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | PANITUMUMAB | PANITUMUMAB | 19223544 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Oxaliplatin | OXALIPLATIN | 24100628 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | DETD-35 | | 27048951 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | cisplatin | CISPLATIN | |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Copanlisib | COPANLISIB | 27672108 |
5728 | PTEN | PTEN FAMILY, ENZYME, PROTEIN PHOSPHATASE, DRUG RESISTANCE, CLINICALLY ACTIONABLE, KINASE | | Fulvestrant | FULVESTRANT | 26733612 |